10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Rigel has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, Rigel, MAR 3, 2015, View Source [SID1234502165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

MacroGenics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, MacroGenics, MAR 3, 2015, View Source [SID1234502164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

François Legault is appointed Chairman of the Board of Verlyx Pharma, a biopharmaceutical company developing products targeting liver diseases.

On March 3, 2015 Verlyx Pharma Inc. reported the appointment of François Legault as Chairman of the Board, effective immediately (Press release, Verlyx Pharma, MAR 3, 2015, View Source [SID:1234513486]). Mr. Legault, a seasoned biotechnology and industrial technologies executive, joins Verlyx with more than 25 years of experience in the biotechnology sector.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we seek to move forward and establish the company as a frontrunner in the treatment of inflammatory liver diseases such as NASH (non-alcoholic steatohepatitis), we identified a remarkable leader who could bring vision, focus and a wealth of experience to maximize Verlyx’s potential," said Bernard Dorval, Acting Chairman of the Board. "The Board and shareholders are confident that François’ rich experience in the biotechnology sector, and in particular in the area of liver diseases, as well as his passion for leading high performing teams will help Verlyx establish itself as a leader in this field."

Mr. Legault was President, Chief Operating Officer and a cofounder of ViroChem Pharma Inc., a private biotechnology company which was acquired by Vertex Pharmaceuticals. Prior to that, he was a Senior Officer of BioChem Pharma Inc., another important biopharmaceutical company, from its inception until the company merged with Shire Pharmaceuticals Group plc.

"I am delighted to join Verlyx Pharma at a time when it is establishing its first-in-man clinical proof of concept with VLX103, focusing on the treatment of liver diseases," said François Legault, Verlyx’s new Chairman. "There are important unmet needs in this field which represent huge opportunities for the company’s portfolio of products. I am looking forward to working both with the Board and the management team led by Pierre Falardeau, President and Chief Executive Officer, as we advance our products toward commercialization."

Earlier today, Oncozyme Pharma had announced that it was changing its corporate name to Verlyx Pharma Inc. to reflect the corporation’s new focus on targeting inflammatory liver diseases. Verlyx Pharma, a privately held company, is dedicated to the discovery and development of drugs to treat liver disorders. The company’s lead product, VLX103, is a potent agent with hepatoprotective activity, specifically designed to target the liver and minimize non-targeted systemic exposure. Such properties give it an ideal profile for the treatment of liver diseases such as NASH and ASH (Free ASH Whitepaper) (alcoholic steatohepatitis). An increasing number of people are expected to be affected by liver diseases worldwide, and many analysts are calling NASH "the next big global epidemic".

Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programs

On March 3, 2015 Domain Therapeutics, a biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), reported the creation of a Specific Purpose Vehicle (SPV), Kaldi Pharma, for the exclusive development of its A2a/A1 and A2a antagonist programs (Press release, Domain Therapeutics, MAR 3, 2015, View Source;domain-therapeutics—kaldi-pharma-en.pdf [SID:1234508324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The mission of Kaldi Pharma is to exploit the patented series of A2a/A1 and A2a antagonists discovered by Domain Therapeutics in any indication in which inhibiting adenosine constitutes a valuable therapeutic approach.

Kaldi Pharma has granted a worldwide license to Clevexel Pharma for the development of the A2a/A1 preclinical candidate for Parkinson’s disease. CleveXel and Kaldi Pharma signed an agreement for sharing future revenues on the program.

Kaldi Pharma is expected to grant a second license for the A2a in oncology to another partner. It has recently been revealed that combining an A2a antagonist with immune checkpoint blockers results in enhanced antimetastatic effects.

After having entrusted the development of a first product to Prexton Therapeutics, with this SPV, Domain reaffirms its strategy to move forward the development of its products up to clinical proof-of-concept through dedicated entities enabling a flexible approach and an optimized value creation of its programs.

"For CleveXel, this partnership with Kaldi paves the way for real development of our company. We are very pleased with this license on the innovative molecule for Parkinson’s disease. CleveXel’s expertise in drug development will undoubtedly add value to this program," said Christian Bloy, President of CleveXel Pharma. "We will make this product a flagship project in our portfolio and take it through to clinical development."

"We are very excited by the creation of Kaldi and by the considerable potential of our novel generation of adenosine antagonists as drugs against Parkinson and cancer," said Pascal Neuville, CEO of Domain Therapeutics and president of Kaldi Pharma. "CleveXel is the perfect partner for Kaldi in CNS indications with their solid expertise in preclinical and clinical drug development."

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

On March 4, 2015 Coronado Biosciences reported the formation of a new subsidiary company, Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber). Dr. Marasco will chair the Scientific Advisory Board of the Company (Press release, Coronado Biosciences, MAR 4, 2015, View Source;FID=1001195572 [SID:1234502186]). Under the terms of the agreement, Checkpoint will pay Dana-Farber an up-front licensing fee in addition to development and sales-based milestone payments and royalties on net sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The portfolio of antibodies licensed from Dana-Farber includes antibodies targeting PD-L1, GITR and CAIX. Checkpoint plans to develop these novel immuno-oncology and checkpoint inhibitor antibodies on their own and in combination with each other, as data suggests that combinations of these targets can work synergistically together. Clinical trials are expected to start in the second half of next year.

In connection with the license agreement with Dana-Farber, Checkpoint Therapeutics entered into a collaboration agreement with TG Therapeutics, Inc. (Nasdaq:TGTX) to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint retains the right to develop and commercialize these antibodies in solid tumors. Both programs are currently in pre-clinical development. Under the terms of the agreement, TG Therapeutics will pay Checkpoint an up-front licensing fee as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.

Dr. Lindsay A. Rosenwald, Chairman and CEO of Coronado Biosciences stated, "We are absolutely delighted to partner with one of the pioneers in this field, Dr. Wayne Marasco." Dr. Rosenwald continued, "Immuno-oncology is one of the most exciting areas in cancer drug development. Drugs that inhibit key immune checkpoint proteins have the potential to unlock the immune system to kill cancer cells. Results for PD-1 inhibitors in melanoma and lung cancer have been impressive but these are early innings of a long game to optimize the right combination of checkpoint inhibitors and other targeted agents to provide lasting cures to all patients. The early work will pave the way for novel combinations, which is where Checkpoint plans to play a pivotal role. The three antibodies licensed today may work synergistically together as well as with other agents. To accelerate development in one area, hematological malignancies, Checkpoint partnered with TG Therapeutics. With TG’s impressive early results with its drug candidates, expertise and relationships in hematological malignancies, we believe we can accelerate development of these important antibodies in this area. "

About anti-PD-L1 and anti-GITR
Anti-PD-L1 antibodies target programmed cell death ligand 1 (PD-L1). Signals from PD-L1 on tumor cells and in tumor microenvironment help those tumors avoid immune attack and elimination by preventing activation of tumor specific effector T-cells. Anti-PD-L1 antibodies are designed to block that signal permitting effector T-cells to attack the cancer. Anti-GITR antibodies target glucocorticoid-induced tumor necrosis factor receptor related protein (GITR), which is regularly expressed on the surface of regulatory T-cells (Tregs) and is expressed on the surface of effector T-cells after their activation. Modulation of GITR with agonistic antibodies has been shown to amplify the antitumor immune responses in animal models via multiple mechanisms. Anti-GITR antibodies are designed to activate the GITR receptor thereby increasing the proliferation and function of effector T cells. At the same time, ligation of GITR on surface of Tregs could abrogate suppressive function of these cells on tumor specific effector T-cells thus further augmenting T-cell immune response. While targeting PD-1/PD-L1 axes alone has already demonstrated impressive anticancer efficacy and durable responses in humans, its efficacy appears to be limited to certain patients. It is believed the effects of anti-PD-L1 intervention can be enhanced by utilizing a co-stimulatory antibody, like one targeting GITR, that can turn on tumor specific effector T-cells. Combining immunotherapies like anti-PD-L1 that counters the tumor’s immune-evading defense system with an anti-GITR that activates effector T-cells, represents a rational approach to use the body’s own immune system to help fight cancer. Pre-clinical research on the combination of the two approaches has yielded very encouraging results to support synergistic potential of this combination. Anti-CAIX antibodies target carbonic anhydrase IX (CAIX), which is over-expressed on the surface of renal cell carcinoma (RCC) and hypoxic solid tumors making it a promising therapeutic target. RCC is a significant public health issue with over 60,000 new cases and over 13,000 deaths predicted in US last year. As a number of RCC cases have already been shown to be sensitive to anti-tumor immune response generated as a result of PD-1/PD-L pathway inhibition, it makes it reasonable to attempt improving the response rate in this malignancy further by additional targeting of immune responses to this tumor with other immune stimulating agents such as anti-CAIX and anti-GITR antibodies.